Ponatinib D8 (known also as AP24534 D8) is a octa-deuterated form of Ponatinib (AP-24534), which is an orally bioavailable multi-targeted kinase inhibitor that gained FDA approved in 2012 for the treatment of resistant or intolerant CML and Ph+ ALL.

纯度：≥98%

CAS：1562993-37-6